 The registry will be conducted at about 45 centers in China, where the CYPHER SelectTM Sirolimus-eluting Coronary Stent is commercially available. Data will be collected on 2,500 diabetic patients treated with the CYPHER SelectTM Sirolimus-eluting Coronary Stent only. 